FY2025 · period end Dec '25 · from the 10-K filed Apr 1, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.00B | $0.00B | $0.09B | $0.01B | $0.01B |
| Gross Profit | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Operating Income | negative: -$0.01B | negative: -$0.02B | negative: -$0.02B | negative: -$0.03B | negative: -$0.03B |
| Net Income | negative: -$0.00B | negative: -$0.00B | negative: -$0.00B | negative: -$0.03B | negative: -$0.03B |
| EPS (Diluted) | negative: -$0.37 | negative: -$0.93 | negative: -$1.81 | negative: -$3.85 | negative: -$4.27 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.01B | $0.01B | $0.01B | $0.02B | $0.04B |
| Total Liabilities | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Stockholders' Equity | negative: -$0.01B | negative: -$0.00B | negative: -$0.00B | $0.01B | $0.03B |
| Cash & Equivalents | $0.00B | $0.00B | $0.00B | $0.01B | $0.04B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.01B | negative: -$0.01B | negative: -$0.02B | negative: -$0.03B | negative: -$0.03B |
| Capital Expenditures | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Free Cash Flow | negative: -$0.01B | negative: -$0.01B | negative: -$0.02B | negative: -$0.03B | negative: -$0.03B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 1724.5% | 136975.0% | 6.0% | 52.8% | 45.0% |
| Operating Margin | negative: -2307.0% | negative: -406950.0% | negative: -0.2% | negative: -3.8% | negative: -4.8% |
| Net Margin | negative: -0.0% | negative: -3.3% | negative: -0.0% | negative: -3.7% | negative: -4.6% |
| Return on Equity | 0.2% | 0.5% | 0.7% | negative: -160.9% | negative: -158.7% |
| Return on Assets | negative: -0.2% | negative: -0.2% | negative: -0.1% | negative: -102.3% | negative: -104.4% |
| Debt / Equity | — | — | — | 0.50× | 0.12× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000926617-26-000052 | Jul 6, 2026 | Jul 15, 2026 | Jul 15, 2026 20:12 UTC | EDGAR |
| 8-K | 0000926617-26-000047 | Jun 17, 2026 | Jun 22, 2026 | Jun 22, 2026 13:13 UTC | EDGAR |
| 8-K | 0000926617-26-000045 | Jun 17, 2026 | Jun 17, 2026 | Jun 17, 2026 20:28 UTC | EDGAR |
| 8-K | 0000926617-26-000042 | Jun 5, 2026 | Jun 9, 2026 | Jun 9, 2026 11:48 UTC | EDGAR |
| 8-K | 0000926617-26-000037 | May 20, 2026 | May 26, 2026 | May 26, 2026 13:03 UTC | EDGAR |
| 10-Q | 0000926617-26-000033 | Mar 31, 2026 | May 15, 2026 | May 15, 2026 20:01 UTC | EDGAR |
| 8-K | 0000926617-26-000029 | Apr 26, 2026 | Apr 30, 2026 | Apr 30, 2026 20:56 UTC | EDGAR |
| 10-K | 0000926617-26-000020 | Dec 31, 2025 | Apr 1, 2026 | Apr 1, 2026 19:46 UTC | EDGAR |
Direct links to SEC EDGAR. AWHL has additional filings available on the SEC site.
6 numbers Aspira Women's Health Inc. later changed — same XBRL tag, both filings linked.
Revenues·FY 2023
Major restatementwas$9.2M
Revised up in a 10-K. Any P/S built on the original was 89.5% too high.
Net Income (Loss) Attributable to Parent·FY 2025
Major restatementwas-$12.8M
Revised up.
Net Income (Loss) Attributable to Parent·FY 2024
Major restatementwas-$13.1M
Revised up.
Revenues·FY 2024
Major restatementwas$4M
Revised down in a 10-K.
Net Income (Loss) Attributable to Parent·FY 2023
Major restatementwas-$16.7M
Revised up.
Net Income (Loss) Attributable to Parent·Q3 2022
Major restatementwas-$4.6M
Revised down in a 10-Q.
AWHL is not the only one.
See every restatement we've found across the market — or get an alert the next time AWHL revises a number.
Restatements are detected by comparing every vintage of a fact across all of Aspira Women's Health Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows AWHL's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Aspira Women's Health Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on AWHL yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on AWHL and publish the result to your public profile.
Ask about Aspira Women's Health Inc.
Continue in Workspace — cited answers on AWHL, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs